Colistimethate sodium dry powder inhalation - Allergan

Drug Profile

Colistimethate sodium dry powder inhalation - Allergan

Alternative Names: Colistimethate sodium inhalation powder - Forest; Colobreathe

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Forest Laboratories
  • Developer Allergan
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 28 Apr 2017 No recent reports on development identified - Preregistration for Cystic fibrosis-associated respiratory tract infections in Brazil (Inhalation)
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 06 Jan 2014 Preregistration for Cystic fibrosis-associated respiratory tract infections in Brazil (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top